Evidence map›Paper›PMID 31165369›Full record

ArticleJournal of neurovirology2019

Efavirenz is associated with altered fronto-striatal function in HIV+ adolescents.

Stéfan Du Plessis, Alexander Perez, Jean-Paul Fouche, Nicole Phillips, John A Joska, Matthijs Vink, Landon Myer, Heather J Zar, Dan J Stein, Jacqueline Hoare

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neurovirology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Stéfan Du PlessisDepartment of Psychiatry, Faculty of Heath Sciences, Stellenbosch University, Francie van Zijl Avenue, Tygerberg, Cape Town, South Africa. stefandup@sun.ac.za.ORCID 0000-0001-9750-5731
Alexander PerezDivision of Epidemiology and Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa.
Jean-Paul FoucheDepartment of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
Nicole PhillipsDepartment of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
John A JoskaDepartment of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
Matthijs VinkDepartments of Experimental and Developmental Psychology, Utrecht University, Utrecht, The Netherlands.
Landon MyerDivision of Epidemiology and Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa.
Heather J ZarDepartment of Pediatrics & Child Health, Red Cross Children's Hospital, UCT, Cape Town, South Africa.
Dan J SteinDepartment of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
Jacqueline HoareDepartment of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZASouth African Medical Research Council · ZAStellenbosch University · ZAUtrecht University · NL

Funding

Cape Town Adolescent Antiretroviral Cohort (CTAAC)R01HD074051 · NICHD · UNIVERSITY OF CAPE TOWN · PI ZAR, HEATHER JOY · 2012 to 2016
$3.0M
NICHD NIH HHS R01 HD074051NICHD NIH HHS R01HD074051
6 · The paper itself

Abstract

Neurotoxicity associated with the antiretroviral efavirenz (EFV) has been documented in HIV-infected adults, but there are no data on the impact of EFV on brain function in adolescents. We investigated potential alterations in fronto-striatal function associated with EFV use in adolescents. A total of 86 adolescents underwent a Stop Signal Anticipation Task (SSAT) during functional MRI (fMRI), 39 HIV+ adolescents receiving EFV, 27 HIV+ adolescents on antiretroviral therapy without EFV (matched on age, gender, education, CD4 cell count and HIV viral load) and 20 HIV- matched controls (matched on age and gender). The task required participants to give timed GO responses with occasional STOP signals at fixed probabilities. Reactive inhibition was modelled as a correct STOP response and proactive inhibition was modelled after response slowing as the STOP probability increases. A priori mask-based regions associated with reactive and proactive inhibition were entered into two respective multivariate ANOVAs. The EFV treatment group showed significantly blunted proactive inhibitory behavioural responses compared to HIV+ adolescents not receiving EFV. There was no difference in reactive inhibition between treatment groups. We also demonstrated a significant effect of EFV treatment on BOLD signal in proactive inhibition regions. There was no difference in regions involved in reactive inhibition. We found no differences between adolescents not receiving EFV and HIV- controls, showing that functional and behavioural differences were unique to the EFV group. Here, we demonstrate for the first time a potential adverse impact of EFV on higher cortical function in young HIV+ adolescents.

Indexed as

AlkynesBenzoxazinesBrainChildCyclopropanesFemaleHIV InfectionsHumansMagnetic Resonance ImagingMaleReverse Transcriptase InhibitorsAlkynesBenzoxazinesCyclopropanesefavirenzReverse Transcriptase InhibitorsAdolescenceEfavirenzfMRIHIV

Identifiers

PMID31165369
PMCPMC6891144
OpenAlexW2948842662

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.